To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory ...

Number 5: Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness. Number 4: High adherence rates, ...

Jonathan Kay, MD, defines biosimilarity and the necessary requirements for that designation and discusses the implications of interchangeability on patient access to biological products.

Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab). Teva and Samsung Bioepis have ...

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for ...

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical ...